Patents by Inventor Scott S. Verbridge
Scott S. Verbridge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12083339Abstract: Described herein are methods of electroporation that can include the steps of contacting a cell that is responsive to an EphA2 receptor ligand with an amount of an EphA2 receptor ligand and applying high-frequency irreversible electroporation to the cell. Also described herein are methods of treating cancer in a subject in need thereof, wherein the methods can include the steps of administering an amount of an EphA2 receptor ligand and applying high-frequency irreversible electroporation to a location on or within the subject.Type: GrantFiled: October 6, 2017Date of Patent: September 10, 2024Assignees: Virginia Tech Intellectual Properties, Inc., Wake Forest University Health SciencesInventors: Jill W. Ivey, Eduardo L. Latouche, Scott S. Verbridge, Rafael V. Davalos, Glenn J. Lesser, Waldemar Debinski
-
Publication number: 20230355968Abstract: Expansion of cytotoxic T lymphocytes (CTLs) is a crucial step in almost all cancer immunotherapeutic methods. Current techniques for expansion of tumor-reactive CTLs present major limitations. The present invention comprises a novel method to effectively produce and expand tumor-activated CTLs using high-voltage pulsed electric fields. Tumor cells were subjected to high-frequency irreversible electroporation (HFIRE) with various electric field magnitudes and pulse widths, or irreversible electroporation (IRE). The treated tumor cells were subsequently cocultured with CD8+ cytotoxic T cells along with antigen-presenting cells. Tumor-activated CTLs can be produced and expanded when exposed to treated tumor cells. The activated CTLs produced with the present invention could be used for clinical applications with the goal of targeting and eliminating tumors.Type: ApplicationFiled: September 22, 2021Publication date: November 9, 2023Inventors: Rafael V. Davalos, Irving C. Allen, Scott S. Verbridge, Nastaran Alinezhadbalalami
-
Publication number: 20230310609Abstract: Described in several embodiments herein are injectable hydrogels that are capable of attracting one or more cells, in situ. In some embodiments, the cells are cancer cells, such as cancer stem cells. Also described herein are methods of using the injectable hydrogels to fill a cavity in a subject. Also described herein are methods of treating a cancer by injecting an injectable hydrogel in a cavity in a subject formed from resecting a tumor and applying an external stimulus to the injected injectable hydrogel or area proximate to the injected injectable hydrogel.Type: ApplicationFiled: August 21, 2021Publication date: October 5, 2023Inventors: Zerin Mahzabin Khan, Scott S. Verbridge, Timothy E. Long, Eli Vlaisavlijevich
-
Publication number: 20230248414Abstract: The present invention relates to the field of biomedical engineering and medical treatment of diseases and disorders. Methods, devices, and systems for in vivo treatment of cell proliferative disorders are provided. In embodiments, the methods comprise the delivery of high-frequency bursts of bipolar pulses to achieve the desired modality of cell death. More specifically, embodiments of the invention relate to a device and method for destroying aberrant cells, including tumor tissues, using high-frequency, bipolar electrical pulses having a burst width on the order of microseconds and duration of single polarity on the microsecond to nanosecond scale. In embodiments, the methods rely on conventional electroporation with adjuvant drugs or irreversible electroporation to cause cell death in treated tumors. The invention can be used to treat solid tumors, such as brain tumors.Type: ApplicationFiled: March 20, 2023Publication date: August 10, 2023Inventors: Michael B. Sano, Christopher B. Arena, Scott S. Verbridge, Rafael V. Davalos
-
Patent number: 11638603Abstract: The present invention relates to the field of biomedical engineering and medical treatment of diseases and disorders. Methods, devices, and systems for in vivo treatment of cell proliferative disorders are provided. In embodiments, the methods comprise the delivery of high-frequency bursts of bipolar pulses to achieve the desired modality of cell death. More specifically, embodiments of the invention relate to a device and method for destroying aberrant cells, including tumor tissues, using high-frequency, bipolar electrical pulses having a burst width on the order of microseconds and duration of single polarity on the microsecond to nanosecond scale. In embodiments, the methods rely on conventional electroporation with adjuvant drugs or irreversible electroporation to cause cell death in treated tumors. The invention can be used to treat solid tumors, such as brain tumors.Type: GrantFiled: June 17, 2019Date of Patent: May 2, 2023Assignee: Virginia Tech Intellectual Properties, Inc.Inventors: Michael B. Sano, Christopher B. Arena, Scott S. Verbridge, Rafael V. Davalos
-
Publication number: 20220362549Abstract: A system and method for selectively treating aberrant cells such as cancer cells through administration of a train of electrical pulses is described. The pulse length and delay between successive pulses is optimized to produce effects on intracellular membrane potentials. Therapies based on the system and method produce two treatment zones: an ablation zone surrounding the electrodes within which aberrant cells are non-selectively killed and a selective treatment zone surrounding the ablation zone within which target cells are selectively killed through effects on intracellular membrane potentials. As a result, infiltrating tumor cells within a tumor margin can be effectively treated while sparing healthy tissue. The system and method are useful for treating various cancers in which solid tumors form and have a chance of recurrence from microscopic disease surrounding the tumor.Type: ApplicationFiled: July 12, 2022Publication date: November 17, 2022Inventors: Michael B. Sano, Chirstopher B. Arena, Scott S. Verbridge, Rafael V. Davalos
-
Patent number: 11406820Abstract: A system and method for selectively treating aberrant cells such as cancer cells through administration of a train of electrical pulses is described. The pulse length and delay between successive pulses is optimized to produce effects on intracellular membrane potentials. Therapies based on the system and method produce two treatment zones: an ablation zone surrounding the electrodes within which aberrant cells are non-selectively killed and a selective treatment zone surrounding the ablation zone within which target cells are selectively killed through effects on intracellular membrane potentials. As a result, infiltrating tumor cells within a tumor margin can be effectively treated while sparing healthy tissue. The system and method are useful for treating various cancers in which solid tumors form and have a chance of recurrence from microscopic disease surrounding the tumor.Type: GrantFiled: July 24, 2019Date of Patent: August 9, 2022Assignee: Virginia Tech Intellectual Properties, Inc.Inventors: Michael B. Sano, Christopher B. Arena, Scott S. Verbridge, Rafael V. Davalos
-
Publication number: 20200046967Abstract: Described herein are methods of electroporation that can include the steps of contacting a cell that is responsive to an EphA2 receptor ligand with an amount of an EphA2 receptor ligand and applying high-frequency irreversible electroporation to the cell. Also described herein are methods of treating cancer in a subject in need thereof, wherein the methods can include the steps of administering an amount of an EphA2 receptor ligand and applying high-frequency irreversible electroporation to a location on or within the subject.Type: ApplicationFiled: October 6, 2017Publication date: February 13, 2020Inventors: JILL W. IVEY, EDUARDO L. LATOUCHE, SCOTT S. VERBRIDGE, RAFAEL V. DAVALOS, GLENN J. LESSER, WALDEMAR DEBINSKI
-
Publication number: 20190351224Abstract: A system and method for selectively treating aberrant cells such as cancer cells through administration of a train of electrical pulses is described. The pulse length and delay between successive pulses is optimized to produce effects on intracellular membrane potentials. Therapies based on the system and method produce two treatment zones: an ablation zone surrounding the electrodes within which aberrant cells are non-selectively killed and a selective treatment zone surrounding the ablation zone within which target cells are selectively killed through effects on intracellular membrane potentials. As a result, infiltrating tumor cells within a tumor margin can be effectively treated while sparing healthy tissue. The system and method are useful for treating various cancers in which solid tumors form and have a chance of recurrence from microscopic disease surrounding the tumor.Type: ApplicationFiled: July 24, 2019Publication date: November 21, 2019Inventors: Michael B. Sano, Christopher B. Arena, Scott S. Verbridge, Rafeal V. Davalos
-
Patent number: 10471254Abstract: A system and method for selectively treating aberrant cells such as cancer cells through administration of a train of electrical pulses is described. The pulse length and delay between successive pulses is optimized to produce effects on intracellular membrane potentials. Therapies based on the system and method produce two treatment zones: an ablation zone surrounding the electrodes within which aberrant cells are non-selectively killed and a selective treatment zone surrounding the ablation zone within which target cells are selectively killed through effects on intracellular membrane potentials. As a result, infiltrating tumor cells within a tumor margin can be effectively treated while sparing healthy tissue. The system and method are useful for treating various cancers in which solid tumors form and have a chance of recurrence from microscopic disease surrounding the tumor.Type: GrantFiled: May 12, 2015Date of Patent: November 12, 2019Assignee: Virginia Tech Intellectual Properties, Inc.Inventors: Michael B. Sano, Christopher B. Arena, Scott S. Verbridge, Rafael V. Davalos
-
Publication number: 20190328445Abstract: The present invention relates to the field of biomedical engineering and medical treatment of diseases and disorders. Methods, devices, and systems for in vivo treatment of cell proliferative disorders are provided. In embodiments, the methods comprise the delivery of high-frequency bursts of bipolar pulses to achieve the desired modality of cell death. More specifically, embodiments of the invention relate to a device and method for destroying aberrant cells, including tumor tissues, using high-frequency, bipolar electrical pulses having a burst width on the order of microseconds and duration of single polarity on the microsecond to nanosecond scale. In embodiments, the methods rely on conventional electroporation with adjuvant drugs or irreversible electroporation to cause cell death in treated tumors. The invention can be used to treat solid tumors, such as brain tumors.Type: ApplicationFiled: June 17, 2019Publication date: October 31, 2019Inventors: Michael B. Sano, Christopher B. Arena, Scott S. Verbridge, Rafael V. Davalos
-
Publication number: 20170266438Abstract: A system and method for selectively treating aberrant cells such as cancer cells through administration of a train of electrical pulses is described. The pulse length and delay between successive pulses is optimized to produce effects on intracellular membrane potentials. Therapies based on the system and method produce two treatment zones: an ablation zone surrounding the electrodes within which aberrant cells are non-selectively killed and a selective treatment zone surrounding the ablation zone within which target cells are selectively killed through effects on intracellular membrane potentials. As a result, infiltrating tumor cells within a tumor margin can be effectively treated while sparing healthy tissue. The system and method are useful for treating various cancers in which solid tumors form and have a chance of recurrence from microscopic disease surrounding the tumor.Type: ApplicationFiled: May 12, 2015Publication date: September 21, 2017Inventors: Michael B. Sano, Christopher B. Arena, Scott S. Verbridge, Rafeal V. Davalos